Institution
Temple University
Education•Philadelphia, Pennsylvania, United States•
About: Temple University is a education organization based out in Philadelphia, Pennsylvania, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 32154 authors who have published 64375 publications receiving 2219828 citations.
Topics: Population, Poison control, Anxiety, Health care, Receptor
Papers published on a yearly basis
Papers
More filters
•
TL;DR: The binding of norBUP to opioid and nociceptin/orphanin FQ (ORL1) receptors, and its effects on [(35)S]guanosine-5'-O-(gamma-thio)triphosphate ([(35]S]GTP gamma S) binding mediated by opioid or ORL1 receptors are described and highlighted.
Abstract: Buprenorphine (BUP) is an oripavine analgesic that is beneficial in the maintenance treatment of opiate-dependent individuals. Although BUP has been studied extensively, relatively little is known about norbuprenorphine (norBUP), a major dealkylated metabolite of BUP. We now describe the binding of norBUP to opioid and nociceptin/orphanin FQ (ORL1) receptors, and its effects on [35S]guanosine-5′-O-(γ-thio)triphosphate ([35S]GTPγS) binding mediated by opioid or ORL1 receptors and in the mouse acetic acid writhing test. Chinese hamster ovary cells stably transfected with each receptor were used for receptor binding and [35S]GTPγS binding. NorBUP exhibited high affinities for μ-, δ-, and κ-opioid receptors withKi values in the nanomolar or subnanomolar range, comparable to those of BUP. NorBUP and BUP had low affinities for the ORL1 receptor with Ki values in the micromolar range. In the [35S]GTPγS binding assay, norBUP displayed characteristics distinct from BUP. At the δ-receptor, norBUP was a potent full agonist, yet BUP had no agonist activity and antagonized actions of norBUP and DPDPE. At μ- and κ-receptors, both norBUP and BUP were potent partial agonists, with norBUP having moderate efficacy and BUP having low efficacy. At the ORL1 receptor, norBUP was a full agonist with low potency, while BUP was a potent partial agonist. In the writhing test, BUP and norBUP both suppressed writhing in an efficacious and dose-dependent manner, giving A50 values of 0.067 and 0.21 mg/kg, s.c., respectively. These results highlight the similarities and differences between BUP and norBUP, each of which may influence the unique pharmacological profile of BUP.
329 citations
••
TL;DR: This work presents a meta-analysis of Platelet Function Studies and Hemostasis in relation to Thrombosis and Haemostasis that shows clear trends in prognosis and in particular in cases of high-risk individuals, where the prognosis for survival is poorer for those with high levels of Aspirin resistance.
329 citations
••
TL;DR: A conceptual framework for understanding the relationship of the objective permanent (defensible space) and transient (territorial markers and incivilities) physical environment and the subjective environment to crime is presented in this paper.
329 citations
••
TL;DR: Periodontal diseases are chronic inflammatory disorders encompassing destructive and nondestructive diseases of the periodontal supporting tissues of teeth that are most prevalent among adults and seniors world-wide and with important modifying effects from other local and systemic factors.
328 citations
••
TL;DR: The treatment of primary central nervous system lymphoma with chemotherapy prior to whole-brain radiation therapy (WBRT) has improved outcome considerably in this previously fatal disease.
Abstract: The treatment of primary central nervous system lymphoma with chemotherapy prior to whole-brain radiation therapy (WBRT) has improved outcome considerably in this previously fatal disease. Complete or partial responses to intravenous methotrexate (3.5 gm/sq m with leucovorin rescue every 3 weeks for two to four cycles) were seen in 12 of 13 patients originally treated. A total of 25 patients (including the original 13) have now been treated with one to six cycles of methotrexate every 10 to 21 days prior to WBRT. Twenty-two had partial or complete responses, with a median duration of response of 32 months. Median survival time was 33 months (42.5 months in those responding to therapy). Nine patients are alive and without evidence of disease 9 to 122 months following therapy. Acute and long-term toxicities were minimal. Systemic methotrexate administration prior to WBRT is well tolerated and produces long-term survival.
328 citations
Authors
Showing all 32360 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert J. Lefkowitz | 214 | 860 | 147995 |
Rakesh K. Jain | 200 | 1467 | 177727 |
Virginia M.-Y. Lee | 194 | 993 | 148820 |
Yury Gogotsi | 171 | 956 | 144520 |
Timothy A. Springer | 167 | 669 | 122421 |
Ralph A. DeFronzo | 160 | 759 | 132993 |
James J. Collins | 151 | 669 | 89476 |
Robert J. Glynn | 146 | 748 | 88387 |
Edward G. Lakatta | 146 | 858 | 88637 |
Steven Williams | 144 | 1375 | 86712 |
Peter Buchholz | 143 | 1181 | 92101 |
David Goldstein | 141 | 1301 | 101955 |
Scott D. Solomon | 137 | 1145 | 103041 |
Donald B. Rubin | 132 | 515 | 262632 |
Jeffery D. Molkentin | 131 | 482 | 61594 |